Technical Analysis for POLB - Poolbeg Pharma PLC
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 11.80 | 1.72% | 0.20 |
POLB closed up 1.72 percent on Friday, April 26, 2024, on 58 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Apr 26
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Stochastic Reached Overbought | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 6 hours ago |
| Possible NR7 | about 6 hours ago |
| Down 2% | about 10 hours ago |
| Down 1% | about 10 hours ago |
| 2x Volume Pace | about 10 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Poolbeg Pharma PLC operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. Its products include POLB 001, a Phase-II ready p38 MAP Kinase inhibitor that reduces harmful inflammation in patients with severe forms of influenza; PredictViral Biomarker Platform, a tool for predicting severe diseases; and vaccine discovery platform, which are techniques used in human challenge models to identify vaccine candidates that drive preferential T-Cell immune responses. The company was formerly known as Orph Pharma Limited and changed its name to Poolbeg Pharma PLC in June 2021. Poolbeg Pharma PLC was incorporated in 2021 and is headquartered in London, the United Kingdom.
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Disease Medical Specialties Vaccine Health Sciences Medical Research Influenza Vaccination
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Disease Medical Specialties Vaccine Health Sciences Medical Research Influenza Vaccination
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 12.0 |
| 52 Week Low | 0.1021 |
| Average Volume | 1,937,302 |
| 200-Day Moving Average | 8.56 |
| 50-Day Moving Average | 10.03 |
| 20-Day Moving Average | 10.33 |
| 10-Day Moving Average | 10.64 |
| Average True Range | 0.60 |
| RSI (14) | 72.75 |
| ADX | 27.25 |
| +DI | 28.90 |
| -DI | 11.45 |
| Chandelier Exit (Long, 3 ATRs) | 10.21 |
| Chandelier Exit (Short, 3 ATRs) | 11.01 |
| Upper Bollinger Bands | 11.53 |
| Lower Bollinger Band | 9.13 |
| Percent B (%b) | 1.11 |
| BandWidth | 23.22 |
| MACD Line | 0.42 |
| MACD Signal Line | 0.24 |
| MACD Histogram | 0.182 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.55 | ||||
| Resistance 3 (R3) | 12.46 | 12.13 | 12.42 | ||
| Resistance 2 (R2) | 12.13 | 11.94 | 12.17 | 12.38 | |
| Resistance 1 (R1) | 11.97 | 11.82 | 12.05 | 12.05 | 12.34 |
| Pivot Point | 11.63 | 11.63 | 11.68 | 11.68 | 11.63 |
| Support 1 (S1) | 11.47 | 11.44 | 11.55 | 11.55 | 11.26 |
| Support 2 (S2) | 11.14 | 11.33 | 11.18 | 11.22 | |
| Support 3 (S3) | 10.97 | 11.14 | 11.18 | ||
| Support 4 (S4) | 11.05 |
